These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 10669726

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2.
    Rui L, Fisher TL, Thomas J, White MF.
    J Biol Chem; 2001 Oct 26; 276(43):40362-7. PubMed ID: 11546773
    [Abstract] [Full Text] [Related]

  • 3. Insulin receptor substrate-1 is the predominant signaling molecule activated by insulin-like growth factor-I, insulin, and interleukin-4 in estrogen receptor-positive human breast cancer cells.
    Jackson JG, White MF, Yee D.
    J Biol Chem; 1998 Apr 17; 273(16):9994-10003. PubMed ID: 9545345
    [Abstract] [Full Text] [Related]

  • 4. Insulin-like growth factor I induces preferential degradation of insulin receptor substrate-2 through the phosphatidylinositol 3-kinase pathway in human neuroblastoma cells.
    Kim B, van Golen CM, Feldman EL.
    Endocrinology; 2005 Dec 17; 146(12):5350-7. PubMed ID: 16150916
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Insulin receptor substrate 2 and Shc play different roles in insulin-like growth factor I signaling.
    Kim B, Cheng HL, Margolis B, Feldman EL.
    J Biol Chem; 1998 Dec 18; 273(51):34543-50. PubMed ID: 9852124
    [Abstract] [Full Text] [Related]

  • 7. Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: attenuation of insulin-like growth factor-I-induced GSK-3beta and ERK pathways in adrenal chromaffin cells.
    Satoh S, Yanagita T, Maruta T, Nemoto T, Yoshikawa N, Kobayashi H, Tono T, Wada A.
    Neuropharmacology; 2008 Jul 18; 55(1):71-9. PubMed ID: 18538359
    [Abstract] [Full Text] [Related]

  • 8. Multiple signaling pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase type 1 gene expression in human breast cancer cells.
    Gingras S, Côté S, Simard J.
    Mol Endocrinol; 2000 Feb 18; 14(2):229-40. PubMed ID: 10674396
    [Abstract] [Full Text] [Related]

  • 9. Signalling pathways of insulin-like growth factor-I that are augmented by cAMP in FRTL-5 cells.
    Ariga M, Nedachi T, Akahori M, Sakamoto H, Ito Y, Hakuno F, Takahashi S.
    Biochem J; 2000 Jun 01; 348 Pt 2(Pt 2):409-16. PubMed ID: 10816436
    [Abstract] [Full Text] [Related]

  • 10. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade.
    Shi Y, Yan H, Frost P, Gera J, Lichtenstein A.
    Mol Cancer Ther; 2005 Oct 01; 4(10):1533-40. PubMed ID: 16227402
    [Abstract] [Full Text] [Related]

  • 11. Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells.
    Kim B, Leventhal PS, White MF, Feldman EL.
    Endocrinology; 1998 Dec 01; 139(12):4881-9. PubMed ID: 9832424
    [Abstract] [Full Text] [Related]

  • 12. Growth factor-specific regulation of insulin receptor substrate-1 expression in MCF-7 breast carcinoma cells: effects on the insulin-like growth factor signaling pathway.
    Lassarre C, Ricort JM.
    Endocrinology; 2003 Nov 01; 144(11):4811-9. PubMed ID: 12960057
    [Abstract] [Full Text] [Related]

  • 13. Insulin receptor substrate-2 proteasomal degradation mediated by a mammalian target of rapamycin (mTOR)-induced negative feedback down-regulates protein kinase B-mediated signaling pathway in beta-cells.
    Briaud I, Dickson LM, Lingohr MK, McCuaig JF, Lawrence JC, Rhodes CJ.
    J Biol Chem; 2005 Jan 21; 280(3):2282-93. PubMed ID: 15537654
    [Abstract] [Full Text] [Related]

  • 14. Proteasome inhibitors regulate tyrosine phosphorylation of IRS-1 and insulin signaling in adipocytes.
    Rondinone CM, Kramer D.
    Biochem Biophys Res Commun; 2002 Sep 06; 296(5):1257-63. PubMed ID: 12207909
    [Abstract] [Full Text] [Related]

  • 15. Mono- or dual-phosphorylation of akt kinase is regulated by distinct receptors that involve the common insulin receptor substrate.
    Schnyder B, Lahm H, Pittet M, Schnyder-Candrian S.
    J Recept Signal Transduct Res; 2002 Sep 06; 22(1-4):213-28. PubMed ID: 12503617
    [Abstract] [Full Text] [Related]

  • 16. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells.
    Guvakova MA, Surmacz E.
    Cancer Res; 1997 Jul 01; 57(13):2606-10. PubMed ID: 9205064
    [Abstract] [Full Text] [Related]

  • 17. Blocking ligand occupancy of the alphaVbeta3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells.
    Zheng B, Clemmons DR.
    Proc Natl Acad Sci U S A; 1998 Sep 15; 95(19):11217-22. PubMed ID: 9736716
    [Abstract] [Full Text] [Related]

  • 18. Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.
    Ibrahim YH, Byron SA, Cui X, Lee AV, Yee D.
    Mol Cancer Res; 2008 Sep 15; 6(9):1491-8. PubMed ID: 18819936
    [Abstract] [Full Text] [Related]

  • 19. Insulin receptor substrate (IRS) proteins IRS-1 and IRS-2 differential signaling in the insulin/insulin-like growth factor-I pathways in fetal brown adipocytes.
    Valverde AM, Lorenzo M, Pons S, White MF, Benito M.
    Mol Endocrinol; 1998 May 15; 12(5):688-97. PubMed ID: 9605931
    [Abstract] [Full Text] [Related]

  • 20. Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factor I.
    Auclair M, Vigouroux C, Desbois-Mouthon C, Deibener J, Kaminski P, Lascols O, Cherqui G, Capeau J, Caron M.
    J Clin Endocrinol Metab; 1999 Sep 15; 84(9):3197-206. PubMed ID: 10487687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.